PT45 and MIAPaCa-2 cells have the genetic alterations that characterise pancreatic cancer including activating KRAS mutations, CDKN2A/p16 deletion, and inactivating TP53 mutations that result in deregulated cell cycle control [49]. Here, KRAS is linked to familial pancreatic carcinoma.